secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nexalin Technology, Inc. (NXL)
CIK:        0001527352
Form:       8-K
Filed at:   2025-12-05T23:59:59+00:00
Accession:  0001829126-25-009755
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nexalin releases December 2025 investor presentation; cash $4.4M, no debt, warrants expired
--------------------------------------------------------------------------------

- Financial snapshot: Cash $4.4M, zero debt, 18.2M common shares, 22.3M fully diluted; warrants expired Sept 2025.
- Gen-2 SYNC (15mA) in-clinic device and Gen-3 HALO at-home device with subscription model highlighted.
- Regulatory progress: FDA De Novo strategy for Alzheimer's, insomnia; clearances in China, Brazil, Oman, Israel.
- Clinical results claim 77% insomnia improvement, 74% depression improvement; Alzheimer's cognitive gains noted.
- Go-to-market includes military TBI/PTSD advisory board with former NATO Supreme Commander and DoD official.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527352/000182912625009755/0001829126-25-009755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527352/000182912625009755/nexalintech_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-009755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer